SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66
Search This Board:
Last Post: 12/9/2016 11:58:44 PM - Followers: 550 - Board type: Free - Posts Today: 0


MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.


MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc.
68 Cumberland Street, Suite 301

Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Current Report Filing (8-k) 09/26/2016 04:12:21 PM
#41677  Sticky Note *** 8-K filing: THESE ARE THE CURRENT MAJOR TPX 09/28/16 03:06:56 PM
#42221   In this stock for the past 15+ years. oneifbylan 12/09/16 11:58:44 PM
#42219   and still would have been able bontooth 12/08/16 11:34:46 PM
#42218   if, that biotech med we and her would bontooth 12/08/16 11:19:40 PM
#42217   Are we rich yet?? ctvette2003 12/08/16 03:14:52 PM
#42216   Consider it marked. Did you call the "company" simon wagstaff 12/07/16 02:59:44 PM
#42214   Next stop .001 ! Mark it! Substantial news BCLBCL 12/07/16 08:02:36 AM
#42213   ADCs: A booming field for new cancer-fighting therapies TPX 12/06/16 02:03:22 PM
#42212   New treatment offers hope to melanoma patients TPX 12/06/16 01:55:24 PM
#42211   Cancer study: Immunotherapy before surgery could dramatically improve TPX 12/06/16 01:53:50 PM
#42209   next stop 0.000? Dip66 12/05/16 03:51:51 PM
#42208   CAGR Regenerative Medicine 2017 TPX 12/05/16 12:16:31 PM
#42207   Newmin croaks, MCET is declared to have zero simon wagstaff 12/03/16 10:33:34 AM
#42206   I guess it will end when bontooth 12/03/16 02:37:06 AM
#42205   Comical ctvette2003 12/02/16 09:20:31 PM
#42204   i love how the promoters here are now Dip66 12/02/16 01:47:23 PM
#42203   lol that's hilarious.. Dip66 12/01/16 02:58:03 PM
#42202   Barb tried to sell me some of her "art". simon wagstaff 12/01/16 11:30:57 AM
#42201   you wanted to reach the real company right, Dip66 12/01/16 11:02:34 AM
#42200   14% CAGR growth by cancer immunotherapy market to TPX 12/01/16 10:21:20 AM
#42199   That's Barb and Jerry's home number in Florida, simon wagstaff 12/01/16 09:06:13 AM
#42198   Office: 941.637.9883 Barbara Corbett Investor Relations Dip66 11/30/16 11:13:08 PM
#42197   LMAO the phone HUH you must have the ctvette2003 11/30/16 09:48:47 PM
#42196   Wow MultiCell deleted all their posts on their Dip66 11/30/16 07:25:12 PM
#42195   MCET's phone had been turned off for months, simon wagstaff 11/30/16 10:45:16 AM
#42193   On the phone... call yourself & stop doubting people! BCLBCL 11/30/16 10:34:09 AM
#42192   Did you call on the phone or speak simon wagstaff 11/30/16 10:18:44 AM
#42191   I think TPX is just trying to run ctvette2003 11/30/16 09:56:04 AM
#42190   Spoke with company last week... 90% chance we BCLBCL 11/30/16 09:55:10 AM
#42189   Treating “Solid” Tumors with CAR T Cells TPX 11/30/16 09:52:46 AM
#42188   Immunotherapy Continues to Advance in Melanoma and Other TPX 11/30/16 09:49:19 AM
#42187   These posts have nothing to do at all.with MCET. simon wagstaff 11/30/16 08:06:18 AM
#42186   yes Simon I would have to bontooth 11/30/16 02:50:27 AM
#42185   because, Dip66 it's my opinion that bontooth 11/30/16 02:34:51 AM
#42183   New Approach Could Boost Immunotherapy for Breast Cancer TPX 11/29/16 07:09:41 PM
#42182   Success of Melanoma Immunotherapy Boosted by Cells Grown TPX 11/29/16 07:07:24 PM
#42181   TPX - Keep up the great work MyDogBuster 11/29/16 04:49:26 PM
#42180   Sad really, sort of pathetic. simon wagstaff 11/29/16 03:15:33 PM
#42178   TPX what's the point no one is listening. Dip66 11/29/16 02:37:26 PM
#42177   Immunotherapy Seen as Optimal First-Line Treatment for Advanced Melanoma TPX 11/29/16 02:14:39 PM
#42176   Melanoma Drugs Market - Emerging Trends and New TPX 11/29/16 12:21:27 PM
#42175   Immunotherapy Encompasses More Than Immuno-oncology TPX 11/28/16 07:44:31 PM
#42174   Global Cancer Immunotherapy Market expected to grow at TPX 11/28/16 07:38:28 PM
#42173   years! simon wagstaff 11/28/16 02:27:41 PM
#42172   Where is that PR you been preaching for Dip66 11/28/16 10:29:30 AM
#42170   Immunotherapy Combinations Key in Myeloma TPX 11/26/16 11:51:06 AM
#42169   Cancer Gene Therapy Market – Global Industry Analysis TPX 11/25/16 12:20:20 PM
#42168   Dr. Kumar on Future Treatment Landscape of Multiple TPX 11/25/16 11:58:16 AM
#42167   The Future of Immunotherapy Is Not Stopping at TPX 11/25/16 10:28:04 AM
#42166   Future Applications of Immunotherapy TPX 11/25/16 10:15:07 AM
#42165   Barb just came back from a nice caribbean Dip66 11/24/16 12:33:11 AM